Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

Francesca Trentin; Mariele Gatto; Margherita Zen; Maddalena Larosa; Linda Nalotto; Francesca Saccon; Elisabetta Zanatta; Luca Iaccarino; Andrea Doria

doi:10.1007/s12016-018-8704-1

Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

Clin Rev Allergy Immunol. 2018 Oct;55(2):237. doi: 10.1007/s12016-018-8704-1.

Authors

Francesca Trentin¹, Mariele Gatto¹, Margherita Zen¹, Maddalena Larosa¹, Linda Nalotto¹, Francesca Saccon¹, Elisabetta Zanatta¹, Luca Iaccarino¹, Andrea Doria²

Affiliations

¹ Division of Rheumatology, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy.
² Division of Rheumatology, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy. adoria@unipd.it.

Abstract

The following changes are made for this article: (1.) Maddalena Larosa's given name and surname were inadvertently interchanged. The authorgroup section is now corrected. (2.) The author(s)' decision to opt for Open Choice.

Publication types

Published Erratum